Cardiac AI: Who’s Winning the Billion-Dollar Race?

The fight for the cardiovascular AI market is getting brutal, with venture capital flooding into any platform that claims it can change heart health. But investors are looking past the tech demos and focusing on commercial traction as the only real sign of a winning strategy in this crowded space. The question smart money is asking is a simple one: who is actually winning the market?

The Growth Imperative: Beyond Clinical Validation to Commercial Scale

These days, the only metric that really matters for evaluating an AI health company is sustained revenue growth, fed by expanding enterprise contracts and a rising number of covered lives. Clinical validation and regulatory clearances (like a 510(k) or De Novo classification) are foundational, but they’re just the entry fee to the game. The real test, and the signal for any real investor return, is a company’s ability to turn its tech into a product that gets widely adopted and generates repeatable sales. As regulatory heat inevitably gets turned up, the companies that already have strong health-plan relationships, deployments inside Fortune 500s, and huge volumes of covered lives are the ones showing real resilience and growth. Hello Heart, for example, set a high bar, showing everyone how deep penetration into employer and health-plan networks actually increases revenue and builds a customer base.

Tempus AI: Genomic Depth Meets Clinical Breadth

Tempus AI is a strong example of how to scale an AI health platform. The company went public on June 14, 2024, with a staggering $6.1 billion valuation, raising $410.7 million in its IPO on top of the $3.06 billion it had already raised privately. It has established a strong position. Tempus AI SEC S-1 registration statement The whole strategy hinges on a massive proprietary dataset, a “data moat”, that powers its AI models in oncology and, increasingly, cardiology. While it’s not a pure-play heart health company, Tempus AI’s power to integrate complex genomic and phenotypic data offers a complete AI approach that could seriously change cardiovascular risk assessment and create personalized treatment plans. An early investor like GV (Google Ventures) obviously saw the potential for this deep data integration to create a lasting advantage. For investors, the Tempus story shows the power of a platform that can stretch its AI across multiple therapeutic areas, with a smart expansion into cardiovascular work. That kind of capital and valuation proves investors trust their data-centric business model.

Omada Health: The Cardiometabolic Digital Care Powerhouse

Omada Health is a leading cardiometabolic digital care provider that has grown fast by signing up big enterprise customers and offering them full programs. The company has pulled in $528.5 million over 12 funding rounds, and its latest round on May 27, 2025, shows that investors believe it delivers real health outcomes and saves money for employers and health plans. Their success is built on landing large enterprise contracts, which is how they grew to 1.1 million members as of June 30, 2026, after having already served over two million members since launch across more than 2,000 employers, health plans, and health systems. What’s the model here? It’s a well-rounded digital platform addressing chronic conditions like prediabetes, type 2 diabetes, and hypertension. For investors, Omada is a prime example of how integrated digital care, using AI for personalization and coaching, can win a huge chunk of the market. Their focus on proving ROI for payers and employers is key, as it moves the conversation from user engagement to actual health improvements and lower healthcare spending. Offering complete care, not just a single-point solution, helps Omada capture more of the chronic disease management market, with heart health being a central pillar. Omada Health enterprise customer metrics

Hinge Health: Expanding from Musculoskeletal to Well-rounded Health

Hinge Health, which started as a digital clinic for musculoskeletal (MSK) care, is now expanding to offer broader health solutions, including elements of heart health. While MSK is still their bread and butter, this move signals a bigger ambition to be a complete digital health partner for big employers and health plans. Hinge Health’s massive $854 million in funding over 9 rounds (including a $400 million Series E on October 22, 2021) and its growing list of enterprise customers show it knows how to scale and integrate into the healthcare system. Their MSK success, which uses AI-powered exercise therapy and coaching, gives us a blueprint for how they might use personalized digital interventions for heart care to improve outcomes and cut costs. As of June 30, 2026, Hinge Health was serving 2,929 clients and around 783,000 members. Investors see the value in this “wedge product” strategy: you dominate one area (like MSK), build trust and a powerful commercial engine, and then expand into adjacent, high-need areas like cardiovascular health. This expansion, backed by strong enterprise relationships, suggests significant future growth.

Comparative Analysis: Unpacking the “Who is Winning?” Question

To evaluate which of these companies provides the most complete AI heart health platform, you have to look at their core strengths and growth paths. Tempus AI brings unmatched genomic and clinical data depth, enabling personalized heart care. Its huge capital raises and IPO valuation show Wall Street’s belief in its deep-tech platform. Omada Health excels at complete cardiometabolic digital care, and its long list of enterprise contracts is proof of its commercial execution. Hinge Health, coming from a different angle (MSK), proves the power of a successful commercial model and the advantage of expanding from a “wedge product.” The definition of a “complete” AI heart health platform is evolving beyond a single, all-in-one algorithm. Today, it includes:

• Data Depth: The quality and proprietary nature of the data that fuels the AI (like Tempus AI’s genomic and clinical datasets).
• Program Breadth: The variety of conditions and interventions offered (like Omada Health’s cardiometabolic suite).
• Commercial Reach: The demonstrated ability to sign and scale enterprise contracts with health plans and large employers (a strength for all three, but especially Omada and Hinge Health).

The “who is winning” narrative, then, recognizes different forms of market leadership, not a single victor. Tempus AI leads in deep, AI-native data integration. Omada Health leads in digital cardiometabolic care and enterprise adoption. Hinge Health shows how a successful digital health platform can expand into new, critical areas.

Investor Takeaway: Scalability and Regulatory De-Risking

For investors, the goal is to find business models that can scale and have already baked in regulatory de-risking. Companies with their QMS/ISO 13485 certifications in hand, a clear path for FDA clearances (be it 510(k) or De Novo), and a solid grasp of GMLP principles are simply better positioned for long-term growth. Securing CPT codes and potentially NTAP for new technologies strengthens their market position and provides much-needed reimbursement clarity. AMA CPT code application process The growth metrics, employer relationships, Fortune 500 deployments, covered-lives volume, all serve as expansion signals that show more than just tech. They show market acceptance and a viable business. The winners in AI heart health will be the ones who innovate clinically and also execute perfectly on commercialization, building strong revenue streams that can withstand the increasing regulatory pressure.

Methodology Note

This analysis uses public financial and operational data from sources like Tempus AI’s S-1 filing, public funding announcements for Omada Health and Hinge Health, and their reported enterprise customer metrics. We assess “comprehensiveness” by looking at the breadth of their offerings, the depth of their data, and their actual commercial traction in the very competitive AI health sector.